Effects of a ketogenic diet in overweight women with polycystic ovary syndrome by Paoli A. et al.
Paoli et al. J Transl Med          (2020) 18:104  
https://doi.org/10.1186/s12967-020-02277-0
RESEARCH
Effects of a ketogenic diet in overweight 
women with polycystic ovary syndrome
Antonio Paoli1,2* , Laura Mancin1,3, Maria Cristina Giacona4, Antonino Bianco5 and Massimiliano Caprio6,7
Abstract 
Background: Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women during repro-
ductive age. It is characterised clinically by oligo-ovulation or anovulation, hyper-androgenism, and the presence of 
polycystic ovaries. It is associated with an increased prevalence of metabolic syndrome, cardiovascular disease and 
type 2 diabetes. The onset of PCOS has been associated to several hereditary and environmental factors, but insulin 
resistance plays a key pathogenetic role. We sought to investigate the effects of a ketogenic diet (KD) on women of 
childbearing age with a diagnosis of PCOS.
Methods: Fourteen overweight women with diagnosis of PCOS underwent to a ketogenic Mediterranean diet with 
phyoextracts (KEMEPHY) for 12 week. Changes in body weight, body mass index (BMI), fat body mass (FBM), lean 
body mass (LBM), visceral adipose tissue (VAT), insulin, glucose, HOMA-IR, total cholesterol, low density lipoprotein 
(LDL), high density lipoprotein (HDL), triglycerides (TGs), total and free testosterone, luteinizing hormone (LH), follicle 
stimulating hormone (FSH); dehydroepiandrosterone sulfate (DHEAs), estradiol, progesterone, sex hormone binding 
globulin (SHBG) and Ferriman Gallwey score were evaluated.
Results: After 12 weeks, anthropometric and body composition measurements revealed a significant reduction 
of body weight (− 9.43 kg), BMI (− 3.35), FBM (8.29 kg) and VAT. There was a significant, slightly decrease of LBM. A 
significant decrease in glucose and insulin blood levels were observed, together with a significant improvement of 
HOMA-IR. A significant decrease of triglycerides, total cholesterol and LDL were observed along with a rise in HDL lev-
els. The LH/FSH ratio, LH total and free testosterone, and DHEAS blood levels were also significantly reduced. Estradiol, 
progesterone and SHBG increased. The Ferriman Gallwey Score was slightly, although not significantly, reduced.
Conclusions: Our results suggest that a KD may be considered as a valuable non pharmacological treatment for 
PCOS. Longer treatment periods should be tested to verify the effect of a KD on the dermatological aspects of PCOS.
Trial registration Clinicaltrial.gov, NCT04163120, registrered 10 November 2019, retrospectively registered, https ://clini 
caltr ials.gov.
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Background
Polycystic ovarian syndrome (PCOS) is considered 
the most common endocrine disorder in women in the 
reproductive age, with an estimated prevalence ranging 
from 6 to 15%, depending on the diagnostic criteria used. 
PCOS, in fact, is an heterogeneous condition with vari-
able phenotypic expression leading to significant contro-
versy on the diagnostic criteria [1].
Women with PCOS often seek care for menstrual 
disturbances (oligomenorrhea, amenorrhea, prolonged 
irregular menstrual bleeding), clinical manifestations 
of hyperandrogenism and infertility. Hirsutism is a 
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occurring in up to 70% of women with PCOS and is 
evaluated using the Ferriman–Gallwey scoring system 
[2].
Common signs of PCOS not included in diagnostic cri-
teria are represented by insulin resistance, reversal of the 
FSH/LH ratio and obesity, which is an important clinical 
feature of PCOS. Women with PCOS have increased vis-
ceral and subcutaneous body fat due to higher androgen 
levels. Obesity also plays a significant role in explaining 
the metabolic characteristics of PCOS: patients display 
an atherogenic lipid profile, associated with elevated 
levels of low-density lipoprotein, triglycerides and cho-
lesterol, along with reduced levels of high-density lipo-
protein [3]. However, it is important to remark that these 
metabolic abnormalities may also be present in non-
obese patients [4]. The positive correlations between 
hyperinsulinemia and androgen levels suggested that 
insulin contributes to hyperandrogenism in women with 
PCOS. The ovaries of PCOS patients usually maintain a 
normal response to insulin. A partial elucidation of this 
mechanism is explained by the action of insulin on the 
ovary through the IGF-1 receptor. This binding occurs 
when insulin reaches high concentrations, as in com-
pensatory hyperinsulinemia. Insulin actions on the ovary 
are also mediated by the glycan molecules that contain 
D-chiro-inositol (DCI) [5], a different second messenger 
from the classical one activated by phosphorylation of 
the receptor at tyrosine level in other tissues. Hyperinsu-
linemia stimulates thecal cell proliferation, amplifies LH-
mediated androgen secretion and increases expression 
of LH and IGF-1 receptor [6]. Furthermore, high insulin 
levels inhibit both the production of sex hormone bind-
ing globulin (SHBG) by the liver, causing increased lev-
els of free testosterone [7], and the synthesis of IGF-BP1, 
increasing level of free IGF-1 [8].
Interestingly, excess carbohydrate intake and low-grade 
inflammation mutually interact with insulin resistance 
and hyperandrogenism to reinforce the metabolic pheno-
type of PCOS [9]. In fact, acute hyperglycaemia is known 
to increase inflammation and oxidative stress through 
generation of reactive oxygen species (ROS) [10]. PCOS 
women present a peculiar dietary pattern, characterised 
by reduced use of extra-virgin olive oil, legumes, seafood 
and nuts, a lower amount of complex carbohydrate, fiber, 
monounsaturated fatty acids, and higher simple carbo-
hydrates, total fat and saturated fatty acid, compared to 
normal women. These nutritional habits are associated to 
an adverse body composition, characterised by reduced 
fat-free mass [11].
A univocal therapy for PCOS does not exist; the pecu-
liar heterogeneity of this pathology requires that the 
treatment should be personalized, depending on the clin-
ical presentation and needs of the patient.
The current guidelines as first-line treatment for men-
strual irregularities, acne and hirsutism recommend 
hormonal contraceptives, at any age. Antiandrogens are 
suggested in the case that estroprogestinics are contrain-
dicated or in the presence of severe hirsutism.
Metformin has long been used in therapeutic proto-
cols, although alternatives are investigated, because of 
gastroenteric side effects; inositol represents an alter-
native approach. Anyway, metformin does not increase 
weight loss in patients treated with lifestyle modifi-
cations (diet and exercise programs). Therefore, diet 
and exercise, not metformin, should be the first line of 
therapy in obese women with PCOS. Metformin should 
be considered if the patient fails with diet and exercise 
[12]. Weight loss represents the most important fac-
tor to improve PCOS phenotype. A 5–10% weight loss 
improves ovulatory function and pregnancy rates, with 
reduction of insulin and free testosterone levels. How-
ever, even though lifestyle modification based on the 
principles of caloric restriction remains a primary ther-
apy for PCOS and caloric restriction seems more impor-
tant than macronutrient composition [13, 14], little data 
are available about diet’s macronutrient modification as 
therapeutic approach [15–17]. Indeed, it is controversial 
whether diet composition per se has an effect on repro-
ductive and metabolic outcomes. Blood glucose levels 
are affected by carbohydrate intake and regulate insulin 
secretion from the pancreas, so very-low carbohydrates 
diets may be superior to standard hypocaloric diets in 
terms of improving fertility, endocrine/metabolic param-
eters, weight loss and satiety in women with PCOS [18]. 
Considering the all aforementioned conditions it would 
be reasonable that a ketogenic diet (KD) might has posi-
tive effects on PCOS. A KD is a nutritional protocol in 
which carbohydrates are lower than 30 g per day or 5% of 
total energy intake [19–21] relative increase in the pro-
portions of protein and fat. The reduction of the amount 
of circulating glucose and insulin produces a reduction 
of the oxidation of glucose and an increase of the fat 
oxidation as showed by the reduction of the respiratory 
ratio [22] Another important effects of KD for PCOS is 
the activation of AMPK and SIRT-1, even in the absence 
of caloric deprivation [23]. Once activated, SIRT1 and 
AMPK produce beneficial effects on glucose homeostasis 
and improve insulin sensitivity [24].
The therapeutic role of KD has been investigated for 
a long time and several works have supported the thesis 
that physiological ketosis can be useful in many patho-
logical conditions, such as epilepsy, neurological diseases, 
cancer (with a ketogenic isocaloric diet) [25] and obesity, 
type 2 diabetes, acne, and the amelioration of respiratory 
and cardiovascular disease risk factors (with a generally 
low calorie ketogenic diet) [26–28]. This is an important 
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aim, since the use of food as a drug has very relevant 
social and economic implications, both in economic and 
social terms. In PCOS, evidence for the effects of KD are 
scarce: only a small uncontrolled pilot study [29] showed 
a significant reduction in body weight, free testosterone, 
LH to FSH ratio, and fasting insulin after a KD regimen, 
suggesting favourable effects in affected patients. Other 
data describe several mechanisms consistent with the 
favourable effects of such diet therapy [30–32]. A recent 
position statement of the Italian Society of Endocrinol-
ogy suggested a weight-loss program with a very low 
calorie ketogenic diet for overweight/obese patients with 
PCOS) not responsive to multicomponent standardized 
diet to improve insulin resistance, ovulatory dysfunctions 
and hyperandrogenemia, even if further controlled stud-
ies are deemed necessary to confirm the beneficial effects 
of KD in this clinical context [28].
Thus, aim of the present study was to determine the 
effects of a ketogenic diet (KD) in women of childbear-
ing age with a diagnosis of PCOS. We hypothesized 
that a modified KD (KEMEPHY diet) would lead to an 
improvement in body weight, plasma cholesterol, triglyc-
erides, hyperinsulinemia and hormonal outcomes.
Materials and methods
Study design
This was a 12  weeks, single-arm study. The outcome 
measures were body weight, BMI, FBM, LBM, FBM per-
centage, LBM percentage, glucose, insulin, HOMA-IR, 
total cholesterol, HDL, LDL, triglycerides, total testos-
terone, free testosterone, progesterone, estradiol, LH, 
FSH, DHEAS, LH/FSH ratio, SHBG and Ferriman Gall-
wey Score. The study protocol complied with all tenets 
of the Helsinki declaration. All patients provided writ-
ten informed consent before the beginning of the study. 
The study was approved by the ethical committee of the 
Department of Biomedical Sciences (HEC-DSB13/16). 
This trial was retrospectively registered on Clinicaltrial.
gov, NCT04163120, registered 10 November 2019, https 
://clini caltr ials.gov.
Participants
Twenty-four overweight women were enrolled trough 
public announcement in medical centers in Padova 
and Vicenza territory. Inclusion criteria were: diagno-
sis of PCOS according Rotterdam Criteria (at least 2 of 
3 between oligo/amenorrhea or amenorrhea, clinical 
signs of hyperandrogenism and polycystic ovary con-
firmed with ultrasound [33]), fertile age (18–45  years); 
BMI ≥ 25  kg/m2, desire to lose weight; acceptance not 
to use contraceptives during the experimental period. 
Exclusion criteria were pregnancy and lactation, hor-
monal therapy and/or insulin-sensitizers in the last 
2  months, hepatic, renal and heart diseases, local treat-
ment for hirsutism, moreover, according to Rotterdam 
criteria, other aetiologies (congenital adrenal hyperpla-
sia, androgen secreting tumours, Cushing syndrome) 
have been excluded. Six women were excluded for cur-
rent PCOS pharmacological therapy and 2 for diagnos-
ticated clinical hypothyroidism. One left the study after 
2 weeks and one withdrew before the follow up; thus 14 
subjects (age 27.5 ± 8.3 years; height 168 ± 4.3 cm; weight 
81.19 ± 8.44 kg) concluded the study (Fig. 1).
Before starting the dietary protocol participants came 
to the Nutrition and Exercise Physiology Laboratory of 
the Department of Biomedical Sciences of the University 
of Padua for the basal measurements. Patients under-
went a detailed anamnesis and physical examination, 
and plasma analysis for glucose, insulin, total cholesterol, 
HDL, LDL, triglycerides (TGs), total testosterone, free 
testosterone, progesterone, estradiol, LH, FSH, DHEAS 
and SHBG were carried out.
Anthropometric measurements
Body weight was measured to the nearest 0.1 kg using an 
electronic scale (Tanita BWB-800 Medical Scales, USA), 
and height to the nearest 1  cm using a wall-mounted 
Harpenden portable stadiometer (Holtain Ltd, UK). Body 
mass index (BMI) was calculated in kg/m2. Waist cir-
cumference was measured as the smallest circumference 
between the lowest rib and the iliac crest [34, 35].
Body composition analysis
Body composition (fat body mass FBM, lean body mass 
LBM and visceral adipose tissue VAT) was analysed by 
Dual X Ray Absorptiometry (DEXA) Hologic  HorizonTM 
QDR RSeries Bedford, Massachusetts, USA. Daily qual-
ity control scans were acquired during the study period. 
No hardware or software changes were made during the 
course of the trial. Subjects were scanned using standard 
positioning protocols, while wearing only light clothing. 
Regional analysis of the trunk and visceral adipose tissue 
VAT were assessed according to anatomical landmarks 
by the same technician using computer algorithms (Apex 
System).
Blood exams
Blood samples were taken from antecubital vein and col-
lected into BD Vacutainers Tubes  (SSTTM II Advance, 
REF 367953). After blood sampling, samples were centri-
fuged (4000 RPM at 4 °C using centrifuge J6-MC by Beck-
man). The serum, so obtained, was aliquoted and stored 
at − 80  °C. All samples were analysed in the same ana-
lytical session for each test using the same reagent lot and 
having CV intraassay < 7%. Before the analytical session, 
the serum samples were thawed overnight at 4  °C and 
Page 4 of 11Paoli et al. J Transl Med          (2020) 18:104 
then mixed. Total testosterone, DHEAS, progesterone, 
estradiol, FSH, LH, insulin and SHBG were measured by 
immunochemiluminescent method (Roche Cobas e601, 
Roche  Diagnostics, Mannheim, Germany), blood glu-
cose by enzymatic method with esokinase (Roche Cobas 
e702, Roche  Diagnostics, Mannheim, Germany), total 
cholesterol, HDL, and LDL by enzymatic colorimetric in 
homogenous phase (Roche Cobas e702, Roche Diagnos-
tics, Mannheim, Germany), TGs by an enzymatic colori-
metric method (Roche Cobas e702, Roche  Diagnostics, 
Mannheim, Germany). Free testosterone was measured 
by RIA radioimmunological test (Beckman Coulter). 
The hormonal status evaluation was performed during 
the follicular phase of the menstrual cycle, between the 
1st and the 7th day. HOMA-IR was calculated accord-
ing to the formula “insulinemia (μU/mL) × glycemia 
(mmol/L)/22.5. At the end of the 12 weeks, the patients 
were re-evaluated in the same way and the collected 
clinical data and DEXA scan results data was statisti-
cally analyzed. Levels of serum 3-hydroxybutyrate (BHB), 
BHB is the most important indicator of ketosis i.e. blood 
level of ketone bodies (KBs), were assessed weekly using 
Precision  Xtra® Blood β-Ketone Test Strips and Preci-
sion  Xtra® [36] (Abbott Laboratories, Illinois 60064-
3500, USA) which measures blood BHB level in fresh 
capillary whole blood from the fingertip between 0.0 and 
8.0 mmol/L. The puncture was performed with the lancet 
Accu-Chek Softclix (Roche, Monza MB, Italy) on clean, 
dry and warm fingers. Hirsutism was considered positive 
when the Ferriman Gallwey Score was > 8.
Diet
A modified KD protocol was used. The KEMEPHY diet 
[37–42] is a Mediterranean eucaloric ketogenic protocol 
(about 1600/1700 kcal/day) with the use of some phyto-
extracts. During this protocol subjects are allowed to eat 
with no limits green leafy vegetables, cruciferous, zuc-
chini, cucumbers and eggplants. The quantity of meat, 
eggs and fish was limited (120 g of meat or 20 g of fish or 
2 eggs) (see Table 1). Moreover, subjects daily consumed 
four food supplements and liquid herbal extracts. Food 
supplements are high proteins (19  g/portion) and very 
low carbohydrate (3.5  g/portion) formulas simulating 
the aspect and taste of common carbohydrate rich foods 
added with dry phytoextracts [43]. Liquid herbal extracts 
were used for their draining/toning activity, useful to 
Fig. 1 Flow chart of experimental design. Recruitment of patients. Further details are reported in the text
Table 1 KEMEPHY diet composition
g % Total E Kcal
Daily total energy 1672 ± 90
 Carbohydrate 20.3 ± 5.2 4.8 ± 1.2 81.5 ± 18.9
 Fat 132.4 ± 11.7 71.1 ± 9.3 1188.2 ± 100.2
 Protein 100.8 ± 8.6 24.1 ± 5.6 403.4 ± 45.3
 Fats distribution % total fats
  Saturated 38.8 ± 6.9
  Monounsaturated 50.9 ± 6.5
  Polyunsaturated 9.7 ± 5.6
Protein (g/Kg body weight) 1.23 ± 0.8
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reduce some commonly reported light side effects of 
ketogenic diets as constipation, headache and halitosis. 
Herbal extracts are reported in more details in our previ-
ous publication (Table 2) [37].
Statistical analysis
A Student’s t test was used to compare parameters before 
and after 12 weeks of the KD, using the software package 
GraphPad Prism version 8.00 for Mac, GraphPad Soft-
ware, San Diego California USA. All data are expressed 
as mean ± standard deviation. Normality of data was 
assessed through the D’Agostino Pearson test. Signifi-
cance was considered at a value of p < 0.05.
Results
Anthropometric and body composition measure-
ments revealed an average weight loss of 9.43  kg (pre 
81.19 ± 8.44  kg vs post 71.76 ± 6.66  kg; p < 0.0001) and 
significant reductions (− 3.35) of BMI (pre 28.84 ± 2.10 vs 
post 25.49 ± 1.69; p < 0.0001) and of FBM (− 8.29 kg) (pre 
27.96 ± 5.11 kg vs post 19.67 ± 3.72 kg; p < 0.0001). LBM 
absolute value showed a slightly significant decrease (pre 
53.23 ± 5.02 kg vs post 52.09 ± 4.60 kg), but its percent-
age value was slightly increased (pre 65.74 ± 3.75% vs 
post 72.71 ± 3.55%; p < 0.0001), with an overall improve-
ment in body composition. VAT showed a very signifi-
cant (pre 1750 ± 181.58 grams vs. post 1110,36 ± 189.23; 
p < 0.0001) decrease and also waist circumference 
decreased in a significant manner (pre 100.7 ± 4.81 vs 
post 96.69 ± 3.82; p = 0.0015). Anthropometric and body 
composition results are presented as mean ± SD in Fig. 2.
Metabolic biomarkers
Ketone bodies were measured every other day for 
the first 6  days, then every 6  days. The mean BHB 
value was 0.31 ± 0.18  mmol/L for the first 6  days and 
1.77 ± 0.55 from day 7 to day 84. Patients at the begin-
ning of the study had a HOMA-IR higher than 2.5, 
confirming insulin resistance. At the end of the study, 
a significant decrease was observed in glucose (pre 
5.10 ± 0.25  mmol/L vs post 4.64 ± 0.24  mmol/L; 
p < 0.0001) and insulin (pre 12.62 ± 0.48 μU/mL vs 
post 11.31 ± 0.60 μU/mL; p < 0.0001) and consequently 
in the HOMA-IR (pre 2.85 ± 0.15 vs post 2.32 ± 0.13; 
p < 0.0001).There were significant changes in lipid profiles 
with reductions in triglycerides (pre 2.31 ± 0.40 mmol/L 
vs post 1.87 ± 0.27 mmol/L; p < 0.0008), total cholesterol 
(pre 5.36 ± 0.36  mmol/L vs post 4.72 ± 0.33  mmol/L; 
p < 0.0001) and LDL (pre 3.11 ± 0.60  mmol/L vs 
post 2.33 ± 0.17  mmol/L; p < 0.0001) along with a 
rise in HDL levels (pre 1.79 ± 0.41  mmol/L vs post 
2.02 ± 0.43 mmol/L; p < 0.0001). The data are reported as 
mean ± SD in Table 3.
Endocrine biomarkers
The characteristic reversal of the LH/FSH ratio was 
observed at the beginning of the study and disappeared 
after 12  weeks (pre 2.00 ± 0.30 vs post 1.15 ± 0.20; 
p < 0.0001).
Compared to basal values, there was also a signifi-
cant decrease in plasma concentrations of LH (pre 
10.24 ± 1.43 vs post 6.41 ± 1.46; p < 0.0001), total testos-
terone (pre 47.43 ± 6.08  ng/dL vs post 40.71 ± 5.77  ng/
dL; p < 0.0001), free testosterone (pre 0.96 ± 0.60  pg/
mL vs post 0.56 ± 0.30 pg/mL; p < 0.0009), percentage of 
free testosterone (pre 2.05 ± 1.33% vs post 2.05 ± 1.33%; 
p < 0.0033) and DHEAS (pre 2.13 ± 0.26  μg/mL vs post 
1.70 ± 0.20 μg/mL; p < 0.0001).
FSH values were found modestly increased, (pre 
5.13 ± 0.51 vs post 5.58 ± 0.65; p = 0.0258), in accord-
ance with the finding that usually in PCOS patients the 
concentration of FSH is not affected by the pathology. 
Estradiol levels were risen (pre 139.80 ± 14.93 pg/mL vs 
post 191.90 ± 38.80 pg/mL; p < 0.0001), so did progester-
one (pre 12.16 ± 1.41  ng/dL vs post 21.06 ± 1.86  ng/dL; 
p < 0.0001). SHBG increased significantly from 26.3 ± 7.9 
to 34.1 ± 8.7 nmol/L; p < 0.0001 (Fig. 3).
The Ferriman Gallwey Score was slightly reduced, 
although not significantly (pre 11.36 ± 1.98 vs post 
10.57 ± 1.6).
Table 2 Plants extract composition
Plant extracts Composition
Extracts 1, ml/day Durvillea antarctica, black radish, mint, liquorice, artichoke, horsetail, burdock, dandelion, rhubarb, 
gentian, lemon balm, chinaroot, juniper, spear grass, elder, fucus, anise, parsley, bearberry, 
horehound
Extracts 2, ml/day Horsetail, asparagus, birch, cypress, couch grass, corn, dandelion, grape, fennel, elder, rosehip, anise
Extracts 3, ml/day Eleuthero, eurycoma longifolia, ginseng, corn, miura puama, grape, guaranà, arabic coffee, ginger
Extracts 4, ml/day Linum usitatissimum L., Gelidium amansii, Rheum officinalis L., Cynara scolymus L., Matricaria chamo-
milla L., Gentiana lutea L., Mentha piperita L., Pimpinella anisum L., Glycyrrhiza glabra L., Raphanus 
sativus L., Foeniculum vulgare Mill., Althaea officinalis L., Melissa officinalis L., Juniperus communis L.
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Discussion
Twelve weeks of LCKD improved almost all anthropo-
metric, biochemical and hormonal variables in a group 
of 14 women with diagnosed PCOS. PCOS, the most 
common female endocrinopathy in reproductive age, is 
characterized by a remarkable phenotypic heterogene-
ity and should not only be considered a fertility or aes-
thetic disorder, but a condition associated with a broad 
spectrum of long-term metabolic and cardio-vascular 
complications. The causes are not known, but the insulin 
resistance is considered an important factor etiopatho-
genetic, that involves 70% of the patients and is in most 
cases linked to overweight and obesity. Abdominal obe-
sity could be linked to PCOS by a relationship in which 
it performs the double role of cause and effect: on the 
one hand, in fact, the increase in visceral fat is favored by 
Fig. 2 Changes in anthropometric variables after 12 weeks of KD. BMI body mass index, FBM fat body mass, LBM mean body mass. Standard 
deviation is represented in the figure. ***p < 0.0001; **p = 0.0015; *p = 0.0205
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hyperandrogenism, on the other it seems to represent an 
important pathogenetic factor in the development and 
progression of the PCOS in susceptible women [44].
The Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS 
Consensus Workshop Group [45] refers that higher BMI 
is associated with a greater prevalence of menstrual 
irregularity, hyperandrogenemia and hirsutism. Adipose 
tissue is, in fact, an extra-glandular source of androgens 
and its excessive quantity can worsen the hyperandro-
genism. Abdominal adipocytes are more active as endo-
crine cells than adipocytes of the lower portion of the 
body, which define gynoid obesity: they are more sensi-
tive to catecholamines and less to insulin, with the end 
Table 3 Metabolic biomarkers before  and  after 12  weeks 
of KD
Standard deviation is reported
LDL low density lipoprotein, HDL high density lipoprotein
Pre Post P value
Glucose (mmol/L) 5.10 ± 0.25 4.64 ± 0.24 < 0.0001
Insulin (μU/mL) 12.62 ± 0.48 11.31 ± 0.60 < 0.0001
HOMA-IR 2.85 ± 0.15 2.32 ± 0.13 < 0.0001
Triglycerides (mmol/L) 2.31 ± 0.40 1.87 ± 0.27 < 0.0008
Total cholesterol (mmol/L) 5.36 ± 0.36 4.72 ± 0.33 < 0.0001
LDL (mmol/L) 3.11 ± 0.60 2.33 ± 0.17 < 0.0001
HDL (mmol/L) 1.79 ± 0.41 2.02 ± 0.43 = 0.0146
Fig. 3 Changes in hormonal variables after 12 weeks of KD. LH luteinizing hormone, FSH follicle stimulating hormone, DHEAs 
dehydroepiandrosterone sulfate, SHBG sex hormone binding globulin. Standard deviation is represented in the figure. ***p < 0.0001; **#p = 0.009; 
**P = 0.0082; *p = 0.0258
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result of a hyperinsulinemia compensatory with low-
grade inflammation, altered lipid profile, increased pro-
duction of androgens and low levels of SHBG, which 
overall favor anovulation. Hyperinsulinemia also influ-
ences metabolic flexibility, the ability of skeletal muscle 
to use alternatively carbohydrates or lipids depending on 
the availability of energy substrates [46]. Women with 
PCOS have more reduced metabolic flexibility (evaluated 
through changes in the respiratory quotient after insulin 
stimulation) when have hyperandrogenism, high BMI 
and Insulin resistance [47, 48].
The management of PCOS is essentially symptomatic: 
when fertility in not the main issue, estroprogestinics 
represent the choice treatment and are often used for 
long periods of time. PCOS patients however have an 
increased cardiovascular risk and a prolonged use of oral 
contraceptives may be negative effects, so the choice of 
an estroprogestinic product should be done after a indi-
vidual cardiovascular risk assessment in all patients. It 
is not the same to use an estroprogestinic product in a 
PCOS patient who has normal weight and has normal 
glucose tolerance and lipid profile or in a PCOS patient 
who is obese and has metabolic syndrome [49]. The 
patients, moreover, do not “heal” with the use of the 
oral contraceptives and after the suspension they often 
have irregularities of the cycle, so that most of them are 
forced to undertake therapies to induce ovulation, usu-
ally with clomiphene, as suggested the guidelines [12]. 
Contraception is therefore an acceptable strategy when at 
the same time an unwanted pregnancy is feared, but for 
many women a different treatment would be much more 
advantageous and desirable.
Guidelines [12] propose hormonal contraceptives as 
first-line management for menstrual abnormalities and 
hirsutism/acne in PCOS whilst metformin is suggested 
as treatment in women with PCOS and Type 2 diabetes 
or impaired glucose tolerance when lifestyle modification 
fail. For women with menstrual irregularities who have 
contraindications or intolerance to estroprogestinics, 
metformin is considered as second-line therapy. Accord-
ing to some experts [50], instead, an attempt with met-
formin, before administering oral contraceptives, should 
however be made, regardless of the contraindications, 
recommending contraception when there is a high risk of 
unwanted pregnancy. Metformin also seems to improve 
the subsequent ovarian response to clomiphene in infer-
tility disorders, with comparable results in both very high 
and non-BMI patients. However, metformin is not free 
from side effects, which often compromise compliance.
The debate on therapy is therefore still on and there is 
often confusion, both among the health professionals and 
among the patients, on who is responsible for the choice 
of treatment: women usually turn to the gynecologist in 
the first instance, because have problems of menstrual 
irregularity and fertility, with disappointment of the 
endocrinologist. Moreover, many women unwillingly 
accept the idea of continuous medicalization and seek 
different solutions.
In this context a central role of a nutritionist could 
be envisaged, in the light of the indications of the same 
guidelines, which now believe that a decisive element in 
the management of PCOS is the modification of lifestyle 
and nutrition.
Several dietary models have been proposed to cor-
rect the metabolic alterations of PCOS, but no one has 
reached, at the moment, a scientific validation as the 
best to recommend and it is still not clear even if nor-
mal weight, or overweight women may take benefit from 
a suitable dietary program to improve insulin resistance 
without caloric restriction. In this context KDs could be 
considered, as a nutraceutical therapy aimed to increase 
insulin sensitivity. The data available in the literature 
[26, 30–32], although few, confirm the assumption that 
a KD, correcting hyperinsulinemia and improving body 
composition, can contribute to the normalization of the 
clinical picture in PCOS. During fasting or a carbohy-
drate restriction such as a KD, blood insulin concentra-
tion decreases, while glucagon increases to maintain the 
normal blood glucose level, first through glycogen stores, 
then through the β-oxidation of fatty acids stored in fat 
depots. Approximately 3–5 days after a very low carbohy-
drate diet, when the concentration of KBs begins to grow, 
hunger considerably decreases, but maintaining a state of 
well-being [51]. The advantage is further substantial if we 
compare common hypocaloric diets which are strongly 
restrictive towards the lipids, which keep the level of the 
orexigenic hormones up to 12 months from the suspen-
sion of the diet [52, 53]. In a physiological state of ketosis 
as during fasting, thanks to the considerable consump-
tion of ketones by the CNS and the balance between insu-
lin and glucagon, ketonemia reaches maximum levels of 
7–8 mmol/L [26], with no change in the pH of the blood. 
During a LCKD the levels of KBs are usually between 
0.5–0.6 and 4 [54–56] and a nutritional ketosis could be 
defined as a blood ketones > 0.5 mmol/L [57–61] Indeed, 
our subjects showed an steep increase in blood BHB dur-
ing the first 6 days reaching, at the end of the first week 
0.55 ± 0.27 mmol/L BHB, whilst the mean value from day 
7 to day 84 was 1.77 ± 0.55 BHB. It is therefore essential 
to make a clear distinction between physiological keto-
sis (KD, fasting) and a pathological ketosis, such as that 
which can occur in diabetes when hyperglycemia and 
insulin deficiency cause uncontrolled rates of KBs and 
the ketonemia may exceed 20  mmol/L, exposing to the 
risk of severe acidosis. Fasting ketosis, however, leads 
to a loss of protein reserves, especially affecting muscle 
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mass and generating a global state of decay. Conversely, 
the ketogenic diet, while maintaining a state of ketosis 
over time due to the limitation of carbohydrates, ensures 
an adequate supply of protein, preserving the tissues 
[20]. It is important to underline that a classic KD is not 
a high-protein diet, but usually has high-fat, adequate-
protein, low-carbohydrate content. In fact, an excess of 
proteins increases gluconeogenesis in the long run, thus 
affecting the synthesis of KBs: in the first days of a KD 
the neoglucogenesis from amino acids represents the 
main source of glucose to keep the glycemia stable, then 
the demand for amino acids decreases and glucose is 
synthesized from the glycerol released from adipose tis-
sue by triglyceride hydrolysis. Our diet was a low calorie 
ketogenic diet in which the amount of protein was high if 
we consider percentage (32%) but normal if we consider 
grams of protein per kilogram of body weight (1.23 g pro/
Kg bw). Such low calorie approach is more feasible dur-
ing a KD (LCKD) because it is well known that ketones 
reduce appetite probably through direct brain actions of 
KBs [51, 62].
The theoretical assumptions for the use of KD in PCOS 
are based on the observation that the physiological keto-
sis induced by a low intake of carbohydrates reduces the 
levels of circulating insulin and consequently also those 
of IGF-1, thus suppressing the stimulus on the produc-
tion of androgens, both ovarian and adrenal. The reduc-
tion of circulating lipids, low-grade inflammation and 
oxidative stress also helps prevent cardiovascular com-
plications [19, 26, 27, 41, 63–65]. Indeed PCOS patients 
are characterized by higher circulating lymphocytes, 
monocytes, eosinophilic granulocytes, as well as higher 
CRP, TNF-α and IL-6, revealing peripheral inflamma-
tion. In addition, polycystic ovaries show persistent 
chronic inflammation with a larger number of infiltrat-
ing inflammatory cells. As TNF-a and IL-6 are known 
to induce insulin resistance, stimulate androgen produc-
tion and disrupt the hypothalamic-pituitary-ovarian axis, 
the increased number of lymphocytes could be an factor 
triggering chronic inflammation and altered hormone 
secretion [66]. Importantly, hyperglycemia can worsen 
inflammation and in PCOS patients glucose ingestion 
induces an inflammatory response that is independent 
of obesity [67]. Ketogenic diet has demonstrated to be 
able to improve inflammatory markers per se [41, 68] also 
due to the action of one of the ketone bodies: 3-hydroxy-
butyrate [69]. The 14 patients enrolled in this study lost 
weight with a significant reduction in FBM accompa-
nied by minimal loss of LBM. This result can be related 
to the inhibition of mTOR by AMPK [70, 71], which is a 
protective role for muscle anabolism: using KD, in fact, 
we never expect to get hypertrophy, but to keep the lean 
mass almost unchanged [72], to difference in extreme 
caloric restriction diets where the loss is usually more 
pronounced.
Insulin resistance was significantly reduced, falling 
below the HOMA-IR threshold of 2.5; also cholesterol 
and triglycerides were significantly lowered. Androgens 
decreased significantly, as did LH and LH/FSH, suggest-
ing a regression of the PCOS hormonal anomalies. The 
improvement in the Ferriman Gallwey Score did not 
reach statistical significance, however, we can be assumed 
that 12 weeks were not sufficient to observe a decrease in 
hirsutism scores: the hair cycle, in fact, depending on the 
body area can last for some months and it is known that 
pharmacological therapy based on antiandrogens takes 
from 6 to 12  months to obtain a good reduction of the 
score.
Conclusions
The results of our study are suggestive for a use of the KD 
as a possible therapeutic aid in PCOS, to be followed by 
a more balanced dietary regimen, but always with par-
ticular attention to the amount of carbohydrates. The 
duration of KD is still a question: there is no evidence of 
side effects in the short term, they are considered safe for 
short cycles. Less information is available on diets in the 
long term, but the experience gained in the field of epi-
lepsy and GLUT-1 deficiency syndrome [73–79] supports 
a possible use also for prolonged periods. It is plausible 
to hypothesize the setting of protocols to be repeated in 
cycles over time, interspersed with periods of balanced 
regime.
Some limitations of the study need to be considered. 
The first is that the effects of a KD on other outcomes 
as oligomenorrea and infertility were not assessed. Sec-
ond, an OGTT for glucose and insulin would have added 
more information about the metabolic effects of a KD, 
unfortunately the experimental setting didn’t allowed us 
to perform this analysis; finally, the small sample size and 
the single arm design therefore further confirmations 
are required, possibly increasing the number of subjects, 
extending the treatment period, and match a low calorie 
ketogenic diet with a low calorie Mediterranean diet.
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